Apremilast for the treatment of psoriatic arthritis

Expert Review of Clinical Pharmacology

Volumn 7, Issue 3, 2014, Pages 239-250

  Varada, Sowmya ^a   Tintle, Suzanne J ^a   Gottlieb, Alice B ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Apremilast; Biologic; Phosphodiesterase inhibitor; Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; APREMILAST; BI 655066; BRODALUMAB; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; FEZAKINUMAB; GOLIMUMAB; GUSELKUMAB; INFLIXIMAB; INTERLEUKIN 17; IXEKIZUMAB; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; MK 3222; NONSTEROID ANTIINFLAMMATORY AGENT; SECUKINUMAB; TILDRAKIZUMAB; TOFACITINIB; UNCLASSIFIED DRUG; USTEKINUMAB; THALIDOMIDE;

ARTHRITIS; DACTYLITIS; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; ENTHESITIS; HUMAN; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; PHARMACODYNAMICS; PSORIATIC ARTHRITIS; REVIEW; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; ARTHRITIS, PSORIATIC; DRUG DEVELOPMENT; IMMUNOLOGY; INTRAARTICULAR DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; BIOPHARMACEUTICS; DRUG DISCOVERY; HUMANS; INJECTIONS, INTRA-ARTICULAR; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84898843259     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.904200     Document Type: Review

References (95)

1. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53(4):573
2. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41(6): 1103-10
3. Rahman P, Nguyen E, Cheung C, et al. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28(5): 1041-4
4. Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol 2011;7(10):588-98
5. Gottlieb AB. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005;4(1): 19-34
6. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54(4):685-704
7. Lowes MA, Russell CB, Martin DA, et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013;34(4):174-81
8. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol 2010;125(6):1261-8; e1269
9. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012;359(1-2):419-29
10. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012;380(9843): 738-46
11. Gladman DD, Thavaneswaran A, Chandran V, Cook RJ. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis 2011;70(12): 2152-4
12. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64(Suppl 2):ii74-7
13. Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001; 19(1 Suppl 22):S17-20
14. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-50
15. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68(9):1387-94
16. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24(3):518-23
17. Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther 2013;7:201-10
18. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50(6):1939-50
19. Cantini F, Niccoli L, Nannini C, et al. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs. J Rheumatol Suppl 2009;83:78-80
20. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33(7):1447-51
21. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014;73(2):349-56
22. Oldfield V, Plosker GL. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrug 2009;23(2):125-35
23. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009;20(2):100-8
24. Borras-Blasco J, Gracia-Perez A, Nunez-Cornejo C, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. J Clin Pharm Ther 2008;33(3):321-5
25. Rallis E, Korfitis C, Stavropoulou E, Papaconstantis M. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction? J Dermatolog Treat 2010;21(1):3-5
26. Shibata S, Tada Y, Komine M, et al. Anti-cyclic citrullinated peptide antibodies and IL-23p19 in psoriatic arthritis. J Dermatolog Sci 2009;53(1):34-9
27. Filer C, Ho P, Smith RL, et al. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum 2008;58(12): 3705-9
28. Malfait AM, Butler DM, Presky DH, et al. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol 1998;111(2):377-83
29. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171(11):6173-7
30. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203(12): 2673-82
31. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/ 23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373(9664):633-40
32. Kim IH, West CE, Kwatra SG, et al. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol 2012;13(6):365-74
33. Gottlieb A, Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis 2013;5(5):277-85
34. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382(9894): 780-9
35. Ritchlin CM, Iain B, Kavanaugh A, et al. Maintenance of efficacy and safety of ustekinumab in patients with active psoriatic arthritis despite prior conventional nonbiologic and anti-TNF biologic therapy: 1 year results of a phase 3, multicenter, double-blind, placebo-controlled trial. 2013 American College of Rheumatology/ ARHP Annual Meeting; 26-30 October 2013; San Diego, CA, USA
36. Stamell EF, Kutner A, Viola K, et al. Ustekinumab associated with flares of psoriatic arthritis. JAMA Dermatol 2013; 149(12):1410-13
37. Stevenson ML, Markowitz O. Selection of therapies in patients with psoriasis and psoriatic arthritis. Psoriasis Forum 2011;17: 144-7
38. Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol 2013; 68(5):863-5
39. Li WQ, Han JL, Manson JE, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol 2012;166(4):811-18
40. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270(2):147-57
41. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011;306(8):864-71
42. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2013;27(5):622-7
43. Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013;27(12):1535-45
44. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford, England) 2003; 42(6):778-83
45. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)- 17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008;159(5): 1092-102
46. Ryan C, Abramson A, Patel M, Menter A. Current investigational drugs in psoriasis. Expert Opin Investig Drugs 2012;21(4): 473-87
47. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012; 366(13):1181-9
48. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13): 1190-9
49. Worcester S. Psoriasis drug MK-3222 progresses through pipeline. Skin & Allergy News 2013. Available from: www. skinandallergynews.com/news/ conferencenews/ american-academy-of-dermatologyannual- meeting-2013/single- article/psoriasisdrug- mk-3222-progresses-through-pipeline/ eab1780ca1924cf44d735207b8823054.html [Last accessed 12 July 2013]
50. Janssen Research & Development L. A Study to assess the pharmacokinetic comparability of guselkumab (CNTO1959) when delivered by 2 different devices and as 2 formulations in healthy participants. Available from: http://clinicaltrials.gov/show/ NCT01866007 [Last accessed 12 July 2013]
51. Pharmaceuticals BI. Single rising dose study of BI 655066 in patients with moderate and severe psoriasis. Available from: http:// clinicaltrials.gov/ ct2/show/NCT01577550? term=BI+655066&rank=1 [Last accessed 12 July 2013]
52. Wolk K, Witte E, Warszawska K, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009; 39(12):3570-81
53. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445(7128):648-51
54. Tintle S, Shemer A, Suarez-Farinas M, et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011;128(3):583-93; e581-584
55. Zenewicz LA, Flavell RA. Recent advances in IL-22 biology. Int Immunol 2011;23(3): 159-63
56. Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 2005;18(4): 243-9
57. Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013; 169(1):137-45
58. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167(3):668-77
59. Pfizer Inc. Tofacitinib in psoriatic arthritis subjects with inadequate response to TNF Inhibitors (OPAL BEYOND). Available from: http://clinicaltrials. gov/ct2/show/ NCT01882439?term=tofacitinib&rank=4 [Last accessed 12 July 2013]
60. Pfizer Inc. Efficacy and safety of tofacitinib in psoriatic arthritis: comparator study (OPAL BROADEN). Available from: http://clinicaltrials.gov/ct2/ show/ NCT01877668?term=tofacitinib+and +psoriasis&rank=6 [Last accessed 12 July 2013]
61. Patel M, Day A, Warren RB, Menter A. Emerging therapies for the treatment of psoriasis. Dermatol Ther (Heidelb) 2012; 2(1):16
62. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2013
63. Nordqvist C. Pfizer's arthritis drug Xeljanz (tofacitinib) receives a negative opinion in Europe. Available from: www. medicalnewstoday.com [Last accessed 12 July 2013]
64. Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 1999;57(9):965-73
65. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012;83(12): 1583-90
66. Christensen SB, Guider A, Forster CJ, et al. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J Med Chem 1998;41(6):821-35
67. O'Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004;25(3):158-63
68. Yu T, Fain K, Boyd CM, et al. Benefits and harms of roflumilast in moderate to severe COPD. Thorax 2013. [Epub ahead of print]
69. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 2010; 159(4):842-55
70. Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4- methoxyphenyl)-2-methanesulfonylethyl]- 1,3-dioxo-2,3-dihy dro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem 2009;52(6):1522-4
71. Muller GW, Corral LG, Shire MG, et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996;39(17):3238-40
72. Manning CD, Burman M, Christensen SB, et al. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999;128(7):1393-8
73. Hidi R, Timmermans S, Liu E, et al. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J 2000;15(2):342-9
74. Brideau C, Van Staden C, Styhler A, et al. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay. Br J Pharmacol 1999;126(4):979-88
75. 5042-107 CR. Evaluation of anti-arthritic activity of CC-10004. Celgene Report CLG/002/EM. 2004
76. Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013;12(8):888-97
77. Schett G, Hayer S, Zwerina J, et al. Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005;1(1):47-54
78. Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford, England) 2006; 45(10):1197-200
79. Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent. apremilast. Curr Med Res Opin 2008;24(5):1529-38
80. Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica 2011;41(12): 1063-75
81. Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64(10):3156-67
82. Kavanaugh A, Mease PJ, Adebajo AO, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis. Ann Rheum Dis 2013;72:Suppl 3 163
83. Cutolo M MG, Fleischmann RM, Liote F, et al. Long-term (52-Week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2). 2013 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; 26-30 October 2013; San Diego, CA, USA
84. Edwards CJ, Blanco FJ, Crowley JH, et al. Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3). 2013 American College of Rheumatology/ Association of Rheumatology Health Professionals Annual Meeting; 26-30 October 2013; San Diego, CA, USA
85. Cutolo M MP, Gladman DD, Kavanaugh A, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in tender and swollen joint counts in patients with psoriatic arthritis: results from three phase 3, randomized controlled trials [abstract 317]. Arthritis Rheum 2013; 65(10 Suppl):S135-6
86. Gladman DD MP, Kavanaugh A, Adebajo AO, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three phase 3 randomized, controlled trials [abstract 816]. Arthritis Rheum 2013; 65(10 Suppl):S347
87. Schett G MP, Gladman DD, Kavanaugh A, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52 -week) improvement in physical function in patients with psoriatic arthritis: results from three phase 3, randomized controlled trials [abstract 331]. Arthritis Rheum 2013; 65(10 Suppl):S143
88. Kavanaugh A. Considerations of psoriatic arthritis therapy selection. 2013 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting; 26-30 October 2013; San Diego, CA, USA
89. Wells AF EC, Adebajo AO, Kivitz AJ, et al. Apremilast in the treatment of DMARD-naive psoriatic arthritis patients: results of a phase 3, randomized, controlled trial (PALACE-4). American College of Rheumatology Annual Meeting Arthritis Rheum 2013. 65
90. Mease PK, Gladman DD, Adebajo AO, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three phase 3, randomized, controlled trials. 2013 American College of Rheumatology/ Association of Rheumatology Health Professionals Annual Meeting; 26-30 October 2013; San Diego, CA, USA
91. Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327(5971):1345-50
92. Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26(11): 2326-35
93. van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis 2014; 73(1):233-7
94. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73(1):48-55
95. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168(2):412-21